Intervention

Teplizumab

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 12 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials12

Recruiting6

Common conditions10

Lead sponsors shown6

Clinical trials

12 shown

Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATGNCT07216391 · 2026-07-29

Long-Term Outcomes of Teplizumab in Routine Clinical CareNCT07360080 · 2026-03-19

Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)NCT07457580 · 2026-03-16

A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United StatesNCT07260110 · 2025-10-31

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 DiabetesNCT07088068 · 2025-08-06

Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 DiabetesNCT06791291 · 2025-07-25

Sequential Immune Modulation and Antigen-Specific Tolerance Induction for Disease Modification in Recent-Onset Type 1 DiabetesNCT07610213 · 2027-01-01

NOT_YET_RECRUITING

Description of Patients With Type 1 Diabetes Treated With TeplizumabNCT06892002 · 2025-02-11

Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)NCT04598893 · 2020-10-26

ACTIVE_NOT_RECRUITING

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)NCT03751007 · 2018-10-24

Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"NCT01030861 · 2010-08-01

The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes MellitusNCT00385697 · 2006-10-01

Common conditions

Type 1 Diabetes Mellitus5 Type 1 Diabetes4 Autoantibody Positive1 Autoimmune Diabetes1 Diabetes Mellitus, Type 11 Diabetes type11 High Risk1 Impaired Glucose Tolerance1 Non-diabetic Relatives at Risk for Type 1 Diabetes1 Type 1 Diabetes Mellitus (T1DM)1

Leading sponsors

Sanofi6 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2 Abdullah Kars1 MacroGenics1 Precigen Actobio T1D, LLC1 Provention Bio, a Sanofi Company1

Trial status mix

RECRUITING6

COMPLETED4

ACTIVE_NOT_RECRUITING1

NOT_YET_RECRUITING1

Phase mix

PHASE25

PHASE12

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.